Literature DB >> 3006303

Inactivation and partition of human T-cell lymphotrophic virus, type III, during ethanol fractionation of plasma.

M A Wells, A E Wittek, J S Epstein, C Marcus-Sekura, S Daniel, D L Tankersley, M S Preston, G V Quinnan.   

Abstract

Because of concern about the safety of immune globulins prepared for injection, we studied the effects of ethanol fractionation of human plasma on human lymphotropic virus, type III, (HTLV-III) by spiking the products of various fractionation steps with HTLV-III. Tests of inactivation and removal indicated that the ratio of residual live virus in plasma fractions/live virus in starting plasma was about 1 X 10(-15) for precipitate II from which immune globulin for injection is manufactured. The results are reassuring regarding the potential safety of immune globulin.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3006303     DOI： 10.1046/j.1537-2995.1986.26286152919.x

Source DB:  PubMed          Journal:  Transfusion        ISSN： 0041-1132            Impact factor:   3.157


  15 in total

Review 1.  Safety and availability of immunoglobulin replacement therapy in relation to potentially transmissable agents. IUIS Committee on Primary Immunodeficiency Disease. International Union of Immunological Societies.

Authors:  H M Chapel
Journal:  Clin Exp Immunol       Date:  1999-10       Impact factor: 4.330

Review 2.  Protein supplementation of human IVF culture media.

Authors:  Deborah Blake; Peter Svalander; Meishan Jin; Christer Silversand; Lars Hamberger
Journal:  J Assist Reprod Genet       Date:  2002-03       Impact factor: 3.412

3.  A history of immune globulin therapy, from the Harvard crash program to monoclonal antibodies.

Authors:  Melvin Berger
Journal:  Curr Allergy Asthma Rep       Date:  2002-09       Impact factor: 4.806

Review 4.  Treatment of sepsis with IgG in very low birthweight infants.

Authors:  A Whitelaw
Journal:  Arch Dis Child       Date:  1990-04       Impact factor: 3.791

Review 5.  Transfusion-associated acquired immunodeficiency syndrome.

Authors:  T A Peterman
Journal:  World J Surg       Date:  1987-02       Impact factor: 3.352

6.  Lack of HIV transmission after hepatitis B immunoprophylaxis.

Authors:  J Genescà; J I Esteban; R Esteban; J M Hernández; J Guardia
Journal:  Infection       Date:  1987       Impact factor: 3.553

7.  Evaluation of the safety and pharmacokinetic profile of a new, pasteurized, human tetanus immunoglobulin administered as sham, postexposure prophylaxis of tetanus.

Authors:  R Forrat; R Dumas; M Seiberling; M Merz; C Lutsch; J Lang
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

Review 8.  The development of virus-free labile blood derivatives--a review.

Authors:  A M Prince; B Horowitz; M S Horowitz; E Zang
Journal:  Eur J Epidemiol       Date:  1987-06       Impact factor: 8.082

9.  Synthetic serum substitute (SSS): a globulin-enriched protein supplement for human embryo culture.

Authors:  P S Weathersbee; T B Pool; T Ord
Journal:  J Assist Reprod Genet       Date:  1995-07       Impact factor: 3.412

10.  Failure of a human immunodeficiency virus (HIV) immune globulin to protect chimpanzees against experimental challenge with HIV.

Authors:  A M Prince; B Horowitz; L Baker; R W Shulman; H Ralph; J Valinsky; A Cundell; B Brotman; W Boehle; F Rey
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.